How were Novelion Therapeutics' earnings last quarter?

Novelion Therapeutics Inc. (NASDAQ:NVLN) posted its earnings results on Thursday, March, 14th. The biotechnology company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by $0.13. The biotechnology company had revenue of $40.71 million for the quarter, compared to analysts' expectations of $40.90 million.

What other stocks do shareholders of Novelion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novelion Therapeutics investors own include Aralez Pharmaceuticals (ARLZ) , Amicus Therapeutics (FOLD) , Applied Genetic Technologies (AGTC) , Advanced Micro Devices (AMD) , Biocept (BIOC) , Karyopharm Therapeutics (KPTI) , Novavax (NVAX) , Rigel Pharmaceuticals (RIGL) , Synergy Pharmaceuticals (SGYP) and Actinium Pharmaceuticals (ATNM) .

NASDAQ:NVLN

Novelion Therapeutics (NVLN) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free NVLN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.68
▼
$0.70
52-Week Range: N/A

Volume: 26,947 shs
Average Volume: 190,529 shs
Market Capitalization: $13.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Novelion Therapeutics alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Novelion Therapeutics Stock (NASDAQ:NVLN)

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

NVLN Stock News Headlines

June 2, 2023 | finance.yahoo.com

CYTO - Altamira Therapeutics Ltd.

See More Headlines

Receive NVLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novelion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2019
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NVLN
CUSIP: N/A
CIK: 827809
Web: www.novelion.com
Phone: 617-500-7867
Fax: N/A
Employees: 109
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-108,330,000.00
Net Margins: -79.43%
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -26.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.24
Quick Ratio: 0.21

Sales & Book Value

Annual Sales: $130.43 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($4.69) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 19,619,000
Free Float: N/A
Market Cap: $13.77 million
Optionable: Optionable
Beta: 2.12

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Benjamin S. Harshbarger (Age 50)
Interim CEO, Gen. Counsel & Corp. Sec.
Mr. Michael D. Price (Age 61)
Exec. VP & CFO
Mr. Roger W. Louis (Age 63)
Global Chief Compliance Officer and Head of R&D
Ms. Barbara Y. Chan (Age 55)
VP & Chief Accounting Officer
Ms. Amanda Murphy
Director of Investor Relations & Corp. Communications

Key Competitors

View All Competitors

NVLN Stock Analysis - Frequently Asked Questions

How were Novelion Therapeutics' earnings last quarter?: Novelion Therapeutics Inc. (NASDAQ:NVLN) posted its earnings results on Thursday, March, 14th. The biotechnology company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by $0.13. The biotechnology company had revenue of $40.71 million for the quarter, compared to analysts' expectations of $40.90 million.
What other stocks do shareholders of Novelion Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Novelion Therapeutics investors own include Aralez Pharmaceuticals (ARLZ), Amicus Therapeutics (FOLD), Applied Genetic Technologies (AGTC), Advanced Micro Devices (AMD), Biocept (BIOC), Karyopharm Therapeutics (KPTI), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and Actinium Pharmaceuticals (ATNM).

This page (NASDAQ:NVLN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Novelion Therapeutics (NVLN) Stock Price, News & Analysis

About Novelion Therapeutics Stock (NASDAQ:NVLN)

NVLN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

NVLN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info